

Special Issue

Probiotics and Nutraceuticals in Human Diseases

Message from the Guest Editor

Human districts exposed to the exterior such as the skin, the digestive tract (from mouth to the intestine), and the vagina are colonized by bacteria, viruses, and fungi that as a whole are referred to as the microbiota. With their metabolism, these microbes produce beneficial nutrients and signaling molecules, yet in circumstances causing dysbiosis, they can promote diseases. Dysbiosis, the alteration in the equilibrium within the microbiota community and the microbiota metabolism, arises from changes in the environment brought forth by infections or unhealthy dietary habits, or abuse of antibiotics. In this Special Issue, we wish to collect original research and review articles highlighting the role and function of probiotics and nutraceuticals (natural products with therapeutic potential) in preventing and curing human chronic diseases such as autoimmune and inflammatory diseases, cancer, infections, and others. Particular emphasis will be on the biochemical/epigenetic/cellular mechanisms of action of probiotics and nutraceuticals and their interaction for explaining the beneficial effects.

Guest Editor

Prof. Dr. Ciro Isidoro

Laboratory of Molecular Pathology, Department of Health Sciences,
Università del Piemonte Orientale "A. Avogadro", Via Solaroli 17, 28100
Novara, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/134261

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).